Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Clin Cancer Res. 2013 Feb 5;19(7):1806–1815. doi: 10.1158/1078-0432.CCR-12-2764

Figure 4. In vivo therapeutic efficacy of sustained EphA2-siRNA-DOPC delivery by discoidal MP in combination with paclitaxel.

Figure 4

Nude mice were inoculated i.p. with SKOV3ip2 cells and randomly divided into eight treatment groups (n = 10): 1) MSV, 2) MSV loaded with non-silencing scramble siRNA-DOPC (MSV/Control, 15 μg siRNA), 3) MSV loaded with 5 μg EphA2-siRNA-DOPC (MSV/EphA2, 5 μg), 4) MSV loaded with 10 μg EphA2-siRNA-DOPC (MSV/EphA2, 10 μg), 5) MSV loaded with 15 μg EphA2-siRNA-DOPC (MSV/EphA2, 15 μg), 6) paclitaxel (PAX), 7) PTX and MSV/Control combination, and 8) PTX and MSV/EphA2 combination. Mice were dosed i.v. biweekly for 6 weeks. They were sacrificed at the end of the treatment, and total tumor weight and tumor nodules were measured. **: p<0.01.

HHS Vulnerability Disclosure